Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast

Rhea-AI Summary

Gamida Cell Ltd. (NASDAQ: GMDA) has scheduled a conference call and live audio webcast for May 10, 2022, at 8:00 a.m. ET, to discuss its Q1 2022 financial results and provide company updates. The event will be accessible via the company's website. Gamida Cell is focused on cell therapies for blood cancers. Its pipeline includes promising therapies like omidubicel, an investigational product aimed at bone marrow transplant patients. Investors are encouraged to stay informed about the company's developments through the webcast and subsequent updates.

Positive

• Gamida Cell's pipeline includes omidubicel, a potential life-saving alternative for bone marrow transplants.

Negative

• Potential risks related to the impact of COVID-19 on clinical trials and business operations.
• Forward-looking statements may not materialize as expected, leading to uncertainties in financial projections.

BOSTON--(BUSINESS WIRE)-- Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, May 10, 2022, at 8:00 a.m. ET to review its first quarter 2022 financial results and provide an update on the company.

The webcast will be available on the “Investors & Media” section of the Gamida Cell website at www.gamida-cell.com. To participate in the live call, please dial 866-930-5560 (domestic) or 409-216-0605 (international) and refer to conference ID number 3344029. A replay of the webcast will be available approximately two hours after the event, for approximately 30 days.

About Gamida Cell
Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapies for patients with solid tumor and blood cancers and other serious blood diseases. We apply a proprietary expansion platform leveraging the properties of NAM to allogeneic cell sources including umbilical cord blood-derived cells and NK cells to create therapies with potential to redefine standards of care. These include omidubicel, an investigational product candidate with potential as a life-saving alternative for patients in need of bone marrow transplant, and a line of modified and unmodified NAM-enabled NK cells targeted at solid tumor and hematological malignancies. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, Twitter, Facebook or Instagram at @GamidaCellTx.

Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to timing of initiation and progress of, and data reported from, the clinical trials of Gamida Cell’s product candidates (including GDA-201), anticipated regulatory filings (including the timing of submission of the BLA for omidubicel to the FDA), commercialization planning efforts, and the potentially life-saving or curative therapeutic and commercial potential of Gamida Cell’s product candidates (including GDA-201 and omidubicel), and Gamida Cell’s expectations for the expected clinical development milestones set forth herein. Any statement describing Gamida Cell’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to the impact that the COVID-19 pandemic could have on our business, and including the scope, progress and expansion of Gamida Cell’s clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 24, 2022, as amended, and other filings that Gamida Cell makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cell’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Gamida Cell’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell. As a result, you are cautioned not to rely on these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005569/en/

For investors:

Courtney Turiano

Stern Investor Relations, Inc.

courtney.turiano@sternir.com

1-212-362-1200

For media:

Rhiannon Jeselonis

Ten Bridge Communications

rhiannon@tenbridgecommunications.com

1-978-417-1946

Source: Gamida Cell Ltd.

FAQ

When is Gamida Cell's next earnings call?

Gamida Cell's next earnings call is scheduled for May 10, 2022, at 8:00 a.m. ET.

What is Gamida Cell's focus in its product development?

Gamida Cell focuses on developing potentially curative cell therapies for blood cancers and serious blood diseases.

What is the investigational product candidate omidubicel?

Omidubicel is an investigational product candidate from Gamida Cell that aims to be a life-saving alternative for patients needing bone marrow transplants.

What are the risks mentioned in Gamida Cell's press release?

The press release mentions risks related to COVID-19's impact on clinical trials and uncertainties in achieving expected financial results.